Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States-Reference-Cited by-同舟云学术

Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States

Published:2020-09-14 Issue:4 Volume:21 Page:699-710
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Goyal Ravi K.¹^ORCID,Cuyun Carter Gebra²,Nagar Saurabh P.¹,Nash Smyth Emily²,Price Gregory L.²,Parikh Rohan C.¹,Huang Yu-Jing²,Li Li²,Davis Keith L.¹,Kaye James A.³

Affiliation:

1. Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

2. Global Patient Outcomes & Real World Evidence (GPORWE), Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

3. Epidemiology, RTI Health Solutions, Waltham, MA, USA

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2020.1804871

Reference39 articles.

1. American Cancer Society. Cancer facts & figures 2019. 2019 [cited 2019 Sept 4]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf

2. Cancer statistics, 2017

3. Breast cancer as a systemic disease: a view of metastasis

4. Extending Survival with Chemotherapy in Metastatic Breast Cancer

5. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer;Cancers;2024-06-07

2. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US;PLOS ONE;2024-05-14

3. Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer;Patient Preference and Adherence;2023-04

4. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study;Cancer;2023-02-09

5. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States;Breast Cancer Research and Treatment;2023-01-07